Morgan Stanley reiterates Alnylam stock Equalweight rating at $360

Revenue rose 65% YoY to $3.71B, while Morgan Stanley reiterated an Equalweight rating with a $360 price target as the stock trades at $308.23 (down 38% from its 52-week high). Key pipeline timing: CARDIO-TTRansform Phase 3 data expected H2 2026 with potential 2027 launch, nucresiran anticipated in 2030, and possible tafamidis genericization earliest Dec 2028. Strategic moves include AI screening partnerships with Viz.ai/AHA (AWARE study), a Tenaya collaboration with up to $10M upfront, a Jefferies downgrade to Hold and a Freedom Capital upgrade to Buy, and a CEO performance award of 55,373 PSUs valued at $18.0M vesting on stock targets by end-2029.

Analysis

Alnylam’s current setup reads like a classic data-driven optionality trade: a material Phase 3 readout in H2-2026 (CARDIO-TTRansform) and a structural tailwind from tafamidis genericization (earliest 12/2028) create distinct catalysts across different horizons. If payors and clinicians embrace combination regimens, the addressable market for silencers could expand meaningfully — a 10-30% uplift in diagnosed/treated ATTR-CM patients over 12–36 months is plausible if AI-enabled screening (AWARE) meaningfully shortens time-to-diagnosis and referral. Conversely, earlier-than-expected entry of Ionis/AZN silencers or faster generic uptake of tafamidis could compress pricing and mix; pricing pressure would primarily hit new starts and late-line combination economics, leaving incumbents with installed base revenue but lower new-patient ARPU.

Second-order beneficiaries include software/AI partners and specialty diagnostics: faster case-finding increases utilization of imaging/triage tools and referral networks, driving >1x revenue leverage for those vendors versus a flat-diagnosis base. Management incentives (performance PSUs tied to multi-year price thresholds) raise the probability of near-term shareholder-friendly actions (buybacks, accelerated commercialization spend) to hit targets, but also increase execution risk if the team stretches guidance to chase vesting. The long-term product roadmap (nucresiran ~2030) preserves upside optionality but creates a multi-year competitive watchlist where smaller players (Ionis, Tenaya as a collaborator) can act as asymmetric downside if they deliver surprise safety/efficacy wins.

Key risk regimes are clear: binary clinical readouts (H2-2026) are 30-60 day volatility events; payer/reimbursement dynamics around tafamidis genericization are 6–24 month processes; and structural competition risk unfolds over 3–5 years. The compound scenario that hurts equity value fastest is a negative CARDIO-TTRansform result combined with faster-than-expected generic penetration — that path can meaningfully re-rate shares within weeks. Monitor diagnostic uptake metrics from the AWARE study and early Wainua market share trends as leading indicators ahead of the Phase 3 readout.

Key Decisions for Investors

• Directional equity with risk control — Buy ALNY shares up to $320 (target $360 in 12 months) with a hard stop at $256 (-20%). Rationale: capture commercialization leverage and H2-2026 Phase 3 optionality while limiting downside from a single binary event; expected reward ~12–25% vs downside capped at 20%.
• Catalyst option play — Buy ALNY Sep-2026 350 calls (or equivalent 9–12 month calls) size ~2% NAV. Objective: asymmetric payout into CARDIO-TTRansform readout; max loss = premium, upside uncapped if data surprises. Consider pairing with a small sale of Sep-2026 650 calls to fund premium if liquidity allows.
• Relative-value pair — Long ALNY / short IONS equal notional (12–24 month horizon). Rationale: Alnylam’s incumbent commercial relationships and diagnostic partnerships should preserve share vs smaller silencer entrants; this neutralizes macro/sector moves and isolates execution/competitive dispersion. Target spread outperformance >30% to justify basis risk.
• Optional asymmetric long in TNYA (small position) — Buy TNYA up to 1% NAV to play downstream partnering upside from Tenaya collaboration and discovery-stage optionality; downside defined by upfront payment size and biotech volatility. Reward: binary partnership/drug target success or follow-on payments could re-rate shares by 2–3x vs expected loss limited to position size.